Ceylan Özgür Ozan, Turan İlyas, Erdemoglu Evrim, González Marina Santos, Magrina Javier
Division of Gynecologic Oncology, Suleyman Demirel University, Isparta 32200, Turkey.
Department of Medical and Gynecologic Surgery, Mayo Clinic, AZ 85054, USA.
Cancers (Basel). 2025 Jun 22;17(13):2086. doi: 10.3390/cancers17132086.
: Bowel resection may be necessary during cytoreductive surgery (CS) in advanced epithelial ovarian cancer to achieve complete tumor removal. However, concerns about increased perioperative risks and unclear survival benefits have led to ongoing debate. This study aimed to evaluate the impact of bowel resection on perioperative mortality and overall survival (OS) in patients undergoing CS. : We retrospectively reviewed 127 patients with FIGO stage IIB-IV epithelial ovarian cancer who underwent primary or interval CS between 2007 and 2021. Patients were stratified based on the performance of bowel resection. Clinical, surgical, and survival data were analyzed using Kaplan-Meier survival analysis and Cox proportional hazards modeling. Primary outcomes were 90-day mortality and OS. : Bowel resection was performed in 58 patients (46%) with more extensive disease and poorer ECOG performance scores. Although the resection group had increased perioperative risks (e.g., higher transfusion rates and ICU use), OS was similar between groups (log-rank = 0.122). Multivariate analysis identified that increasing age (HR = 1.042, = 0.005) was independently associated with poorer OS, whereas lymph node dissection (HR = 0.450, = 0.003) and undergoing primary CS (HR = 0.540, = 0.047) were associated with improved survival. Bowel resection was not independently associated with OS. : Bowel resection does not adversely affect OS when optimal cytoreduction is achieved. Although it increases perioperative complexity, it can be safely incorporated into CS in selected patients. These findings support its use as part of an individualized surgical strategy for advanced ovarian cancer.
在晚期上皮性卵巢癌的肿瘤细胞减灭术(CS)中,可能需要进行肠切除术以实现肿瘤的完全切除。然而,对围手术期风险增加和生存获益不明确的担忧引发了持续的争论。本研究旨在评估肠切除术对接受CS的患者围手术期死亡率和总生存期(OS)的影响。
我们回顾性分析了2007年至2021年间接受初次或间隔期CS的127例国际妇产科联盟(FIGO)IIB-IV期上皮性卵巢癌患者。根据是否进行肠切除术对患者进行分层。使用Kaplan-Meier生存分析和Cox比例风险模型分析临床、手术和生存数据。主要结局为90天死亡率和OS。
58例(46%)病情更广泛且东部肿瘤协作组(ECOG)表现状态评分较差的患者接受了肠切除术。尽管切除组的围手术期风险增加(如输血率和入住重症监护病房的比例更高),但两组之间的OS相似(对数秩检验P = 0.122)。多因素分析确定,年龄增加(风险比[HR]=1.042,P = 0.005)与较差的OS独立相关,而淋巴结清扫(HR = 0.450,P = 0.003)和接受初次CS(HR = 0.540,P = 0.047)与生存改善相关。肠切除术与OS无独立相关性。
当实现最佳肿瘤细胞减灭时,肠切除术不会对OS产生不利影响。尽管它增加了围手术期的复杂性,但在选定的患者中可以安全地纳入CS。这些发现支持将其用作晚期卵巢癌个体化手术策略的一部分。